Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Blood sample of patient with lymphoma. Photo: BSIP/UIG/Getty Images

Researchers are trying to narrow down the reasons why some patients with aggressive lymphoma cancers respond to treatment better than others — and a new study indicates it has to do with subtypes of tumor genes.

Why it matters: Lymphoma is the most common type of blood cancer — non-Hodgkin lymphoma is newly diagnosed in almost 75,000 Americans every year. The new research, published in the New England Journal of Medicine Wednesday, may help target treatments for people.

The background: The National Cancer Institute and other organizations have been studying for about 2 decades the effect of DNA mutations in a patient's tumors on their response to lymphoma treatments, according to study author Louis Staudt of the lymphoid malignancies branch of the NCI's Center for Cancer Research.

  • This latest study focused on the most common form of lymphoma called DLBCL (or diffuse large B-cell lymphoma), which is often aggressive but can be treatable with standard chemotherapy and the drug rituximab.
  • However, previous research found patients with one type of DLBCL called ABC had a 40% average chance of survival while those with a type called GCB had a 75% average survival rate. So, this study tried to pinpoint some of the reasons behind those differences.

What they did: The scientists sequenced and analyzed millions of genetic mutations and the expression of genes in tumor samples from 574 patients with DLBCL. They decided to target recurrent aberrations happening in more than one patient, and then developed an algorithm to determine the genetic subtypes in those common aberrations. They identified 4 prominent genetic subtypes in DLBCL and tested for their response to traditional treatment.

What they found: Of the 4 subtypes, people with subtypes BN2 and EZB are more likely to respond well to treatment, whereas people with MCD and N1 are not likely to respond to chemo/rituximab.

  • However, they also discovered that the MCD subtype, which has the lowest response to traditional treatment (only a 25% survival rate), was similar to a different type of lymphoma, called extranodal lymphoma, which tends to respond well to inhibitors like ibrutinib. Staudt says this means there will likely be more clinical trials testing this.
  • The findings in this "landmark study" mean some doctors "would offer enrollment in a clinical trial using an agent such as ibrutinib, rather than upfront conventional chemotherapy" depending on the patient, Pallawi Torka, an oncologist at Roswell Park Comprehensive Cancer Center in NY, tells Medscape Medical News.
  • Another important surprise finding, Staudt says, is that despite being in the ABC group, one subtype (BN2) actually responds quite well to chemo. This explains why prior studies of the ABC group occasionally showed a patient who responded well to chemo, he says. "Even in what's currently considered the 'bad type' [ABC] of tumors, is what was a 'good' subset."

What's next: More clinical studies are needed to confirm these results, Staudt says. If all goes well he hopes doctors can be implementing new treatment strategies within 5 years. Data from the study, which was funded by the National Institutes of Health and others, will be shared through NCI's Genomic Data Commons for future research and clinical trials.

Staudt says that while "many people are walking the face of the planet because they endured chemo and the cancer's all gone," he expects targeted therapies will be more prominent in future treatments.

Go deeper

Complaint to FTC: Amazon search results full of potentially deceiving ads

Photo: Nigel Kirby/Loop Images/Universal Images Group via Getty Images

Amazon does not sufficiently distinguish between its search results and paid ads, potentially "deceiving millions of consumers," according to a complaint filed to the Federal Trade Commission.

Why it matters: Joan Moriarty, research director for the Strategic Organizing Center, a coalition of labor unions that filed the complaint, told the Washington Post the group is "very hopeful" that the FTC will investigate the complaint because Lina Khan (D), a known Amazon critic, is now chair.

4 hours ago - Health

Pfizer-BioNTech: Booster doses more effective at blocking Omicron

Prepared doses of the BioNtech-Pfizer Covid-19 coronavirus vaccine in Germany on Dec. 7. Photo: Thomas Kienzle/AFP via Getty Images

Pfizer and BioNTech said Wednesday that two doses of their COVID-19 vaccine were significantly less effective at neutralizing the Omicron variant in early lab tests, but a three-dose regimen was more effective.

Why it matters: Omicron, which has been labeled a variant of concern by the World Health Organization after being identified by scientists in South Africa last month, has forced vaccine makers to reassess the effectiveness of their vaccines against this specific new form of coronavirus.

Mike Allen, author of AM
4 hours ago - Politics & Policy

Biden unveils "Building a Better America" branding

President Biden speaks on infrastructure while visiting a bridge in Woodstock, N.H., last month. Photo: John Tully/Getty Images

President Biden today launched a new website and unveiled bold new branding as part of a nationwide tour to sell the benefits of his infrastructure package.

Why it matters: The White House says passage of the new law shows the ability to "forge bipartisan consensus and prove our democracy can deliver big wins" even in these toxic times.